Skip to main content

Advertisement

Table 4 Comparison of demographics and disease manifestations in MPO-ANCA-positive and PR3-ANCA-positive patients

From: Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

  MPO-ANCA PR3-ANCA P value
(n = 125) (n = 13)
Male/female 47/78 6/7 0.56
Mean (median) age (years) 70.0 ± 1.04 (73) 61.3 ± 3.2 (61) 0.012
Serum creatinine (mg/dl) 1.94 ± 0.17 1.22 ± 0.53 0.19
Interstitial lung disease 57 (45.6) 0 (0) 0.0015
Alveolar haemorrhage 11 (8.8) 1 (7.7) 0.89
Disease severity 0.26
 Localised 2 (1.6) 1 (7.7)  
 Early systemic 33 (26.4) 2 (15.4)
 Generalised 68 (54.4) 8 (61.5)
 Severe 22 (17.6) 2 (15.4)
General performancea 0.26
 0/1/2/3/4 16/44/26/31/8 4/6/1/2/0  
BVASb
 BVAS 17.5 ± 0.71 17.5 ± 2.2 0.99
 General 95 (76.0) 10 (76.9) 0.94
 Cutaneous 30 (24.0) 0 (0) 0.046
 Mucous membranes/eyes 16 (12.8) 4 (30.8) 0.08
 Ear, nose, and throat 22 (17.6) 12 (92.3) <0.0001
 Chest 49 (39.2) 7 (53.9) 0.31
 Cardiovascular 8 (6.4) 2 (15.4) 0.23
 Abdominal 2 (1.6) 0 (0) 0.65
 Renal 98 (78.4) 6 (46.2) 0.010
 Nervous system 55 (44.0) 4 (30.8) 0.36
  1. Values expressed as mean ± standard error or number (percentage) unless otherwise noted. Five patients who were double-positive for both ANCAs were excluded from this analysis. ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; PR3, proteinase-3. aGeneral performance was categorised according to the World Health Organization performance status except category 5 (death). bDisease activity and patterns of organ involvement were defined by the BVAS 2003 scoring system.